Navigation Links
Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:11/10/2008

- Conference Call Today at 4:30 p.m. Eastern Time -

SAN FRANCISCO, Nov. 10 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today reported on its corporate progress and financial results for the quarter ended September 30, 2008.

"The third quarter represented another quarter of significant achievement and progress and was capped with the signing of our partnering agreement with Pfizer for Dimebon. This collaboration not only gives us access to a world-class partner capable of maximizing global commercialization, but also provides significant funding allowing us to invest in all of our clinical programs and actively pursue other drug candidates," said David Hung, M.D., president and chief executive officer of Medivation. "We are working with Pfizer on an extensive program to support a broad label for Dimebon in Alzheimer's disease beyond our original plan to pursue the treatment of mild-to-moderate Alzheimer's, and to achieve comprehensive and expeditious regulatory submissions and market acceptance. Accordingly, together we intend to expand development of Dimebon to include new Phase 3 trials in addition to the CONNECTION study. We expect to begin the new trials in 2009 and to file a New Drug Application (NDA) for a broader Alzheimer's disease label in 2011."

Corporate Update

Dimebon: Drug candidate to treat Alzheimer's and Huntington's diseases

-- Entered into an agreement with Pfizer Inc. to jointly develop and

commercialize Dimebon for the treatment of Alzheimer's and Huntington's

diseases. Under the terms of the agreement, Medivation has received an

up-front cash payment of $225 million and is eligible to receive

payments of up to $500 mill
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
2. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
3. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
5. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
6. Medivation Announces Participation in Upcoming Conferences
7. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
8. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
9. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
10. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients
11. Medivation Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... Achieved primarily through a proprietary paraffin and stain additive, ... better detail than the industry standard. But because ... methods, it needed another medium to measure its detail. ... reference because it represents the highest standard of detail ... discovery days of Ultralight Histology was to reverse engineer ...
(Date:5/4/2015)... --  Intrexon Corporation (NYSE: XON ) today ... after the market closes on May 11, 2015.  The ... 5:30 PM ET to discuss the results and provide ... may be accessed by dialing 1-888-346-3959 (Domestic US) and ... Call."  Participants may also access the live webcast through ...
(Date:5/1/2015)... , May 1, 2015 /PRNewswire/ - BioAmber Inc. ... sustainable chemicals, today announced that it has priced an underwritten ... at a price of $9.00 per share, and granted ... purchase up to an additional 585,000 shares of its ... be $35.1 million.  The offering is expected to close on ...
(Date:5/1/2015)... , May 1, 2015 Albany Molecular Research ... William S. Marth , AMRI,s President and Chief Executive ... Lynch 2015 Health Care Conference on Wednesday, May 13, ... audio webcast of the presentation can be accessed at ... The webcast will be archived for 90 ...
Breaking Biology Technology:Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2
... Chakrabarty is modest about the role he played ... willing to do the boasting for him. , , ... patent life forms, visited Wisconsin this week to lecture ... biotechnology program. Asked if he understood the full impact ...
... transportation, and perhaps even the 2016 Olympic games are potential ... according to Milwaukee Mayor Tom Barrett . , ... in a forum held by the Wisconsin Innovation Network, said ... and their plans to develop the "IQ Corridor" along Interstate ...
... and CEO of ZyStor Therapeutics, Inc. is ... of this year's Midwestern bioscience forum. , ,As a ... companies with another presenter, Dr. Irene Hrusovsky, CEO of ... diagnostic products. , ,Like many of the attendees, Peterson ...
Cached Biology Technology:Father of life patents downplays historic role 2Father of life patents downplays historic role 3Cieslewicz, Barrett talk economic collaboration 2Cieslewicz, Barrett talk economic collaboration 3Cieslewicz, Barrett talk economic collaboration 4ZyStor to exhibit cell disorder treatments 2
(Date:4/2/2015)... Germany , April 2, 2015 ... fingerprint tests DERMALOG by far outperforms the strongest ... always maintaining high accuracy, the system is capable ... Hence, the speed proves up to be ten ... faster than its runner-up performance.      ...
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... data to a Phase 2 trial conducted by the ... an 89% survival rate in mantle cell lymphoma patients. ... Historically, patients with this type of lymphoma only have ... 20% chance of surviving 5 years. BiovaxID, an investigational ...
... Florida scientists have found that people have an ancient ... by a jawless, eel-like fish. , It turns out ... road than almost all other backboned animals, may not ... the genetics that govern their skeletal development, according to ...
... in humans are genetically based. The influence of ... of humans are complicated by a multitude of cultural ... Alcoholism: Clinical & Experimental Research use rhesus ... consumption. Results indicate that, just as with humans, ...
Cached Biology News:BiovaxID?yields 89 percent survival in patients with aggressive non-Hodgkins 2UF scientists reveal ancient origin of vertebrate skeleton 2UF scientists reveal ancient origin of vertebrate skeleton 3Genetic and environmental influences on alcohol consumption among rhesus monkeys 2
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
... monoclonal [HDAC8-48] to HDAC8 Regulation ... several mechanisms such as DNA methylation, ... modifications of histones, which include the ... groups of lysine residues present in ...
... polyclonal antibody raised against a ... Immunogen: SLC22A3 (NP_068812, ... partial recombinant protein with GST ... Number: NM_021977 ...
...
Biology Products: